A 2-week, multicenter, randomized, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination tablet in Korean adults with knee osteoarthritis pain

被引:16
|
作者
Chan-Bum, Choi
Song, Jung Soo
Kang, Young Mo
Suh, Chang Hee
Lee, Jisoo
Choe, Jung-Yoon
Lee, Choong Ki
Shim, Seung Cheol
Chung, Won Tae
Song, Gwan Gyu
Kim, Hyun Ah
Ji, Jong Dae
Nam, Eon Jeong
Park, Sung-Hoon
Hong, Young Hoon
Sheen, Dong Hyuk
Lim, Mi Kyoung
Seo, Young Il
Sung, Yoon-Kyoung
Kim, Tae-Hwan
Lee, Jong-Tae
Bae, Sang-Cheol [1 ]
机构
[1] Hanyang Univ, Med Ctr, Hosp Rheumat Dis, Dept Internal Med,Coll Med, Haengdang Dong, Seoul 133792, South Korea
[2] Dankook Univ Hosp, Dept Internal Med, Cheonan, South Korea
[3] Chung Ang Univ, Coll Med, Dept Rheumatol, Seoul 156756, South Korea
[4] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu, South Korea
[5] Ajou Univ, Sch Med, Dept Internal Med, Suwon 441749, South Korea
[6] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[7] Catholic Univ Daegu, Sch Med, Dept Internal Med, Taegu, South Korea
[8] Yeungnam Univ, Coll Med, Dept Internal Med, Taegu, South Korea
[9] Eulji Univ, Sch Med, Dept Internal Med, Taejon, South Korea
[10] Dong A Univ, Coll Med, Dept Internal Med, Pusan, South Korea
[11] Korea Univ, Coll Med, Dept Internal Med, Seoul 136701, South Korea
[12] Hallym Univ, Coll Med, Dept Internal Med, Chunchon, South Korea
[13] Hanyang Univ, Grad Sch, Dept Publ Hlth, Seoul 133791, South Korea
关键词
tramadol; acetaminophen; osteoarthritis; randomized controlled trial;
D O I
10.1016/j.clinthera.2007.07.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Combined tramadol/acetaminophen is used to treat pain related to osteoarthritis. However, adverse events (AEs) leading to discontinuation can occur. Dose titration may decrease the risk for AEs. Objective: The aim of this study was to assess the effect of tramadol/acetaminophen titration on the development of AEs leading to treatment discontinuation in patients with knee osteoarthritis. Methods: This 2-week, multicenter, randomized, double-blind, double-dummy, add-on study was conducted at 12 tertiary referral university hospitals in the Republic of Korea. Patients aged 35 to 75 years with knee osteoarthritis receiving a stable dose of NSAIDs and with a daily mean pain-intensity score of >= 4 on a numeric rating scale (NRS) (0 = no pain to 10 = worst pain) during the 48 hours prior to enrollment were eligible. Patients were randomly assigned to receive 1 tablet of tramadol/acetaminophen 37.5/ 325 mg QD and 1 placebo BID for 3 days, followed by 1 active tablet BID and I placebo QD for 4 days, followed by 1 active tablet TID for 7 days (titration group) or 1 tablet of combined tramadol 37.5 mg/ acetaminophen 325 mg TID for 14 days (nontitration group). The primary outcome measure was the rate of treatment discontinuation due to AEs. Secondary outcome measures were time to discontinuation due to AEs, prevalences and characteristics of AEs, decrease from baseline in pain intensity as measured on the NRS, and change in the Korean version of the Western Ontario and McMaster Universities (K-WOMAC) index score (scale: 0 = best to 100 = worst). Results: A total of 250 patients were enrolled (92.0% female; mean [SD] age, 60.2 [7.8] years; mean [SD] weight, 60.0 [9.2] kg [range, 37.5-90.7 kg]; all Korean). The discontinuation rate was significantly lower in the titration group than in the nontitration group (10.5% vs 26.2%; P < 0.001). The Kaplan-Meier survival curve showed that the rates of discontinuation due to AEs were similar in the 2 groups up to day 2, but thereafter the discontinuation rate was significantly lower in the titration group. The most common AEs were nausea (12.1% and 24.6% in the titration and nontitration groups, respectively; P = 0.008), vomiting (4.0% and 17.2%; P < 0.001), and dizziness (9.7% and 22.1%; P = 0.005). No serious AEs were reported in either group. Tramadol/acetaminophen use was associated with a similar decrease from baseline in pain in both the titration and nontitration groups (mean [SD] Delta s: NRS, -1.60 [1.62] vs -1.68 [1.581; total K-WOMAC, -12.86 [13.73] vs -12.52 [16.58]). Conclusions: In this population of Korean patients with knee osteoarthritis pain managed with a stable dose of NSAIDs, titration of tramadol/acetaminophen over 12 days was associated with improved tolerability and a significantly lower discontinuation rate compared with nontitration. Both regimens significantly reduced from baseline associated with osteoarthritis.
引用
收藏
页码:1381 / 1389
页数:9
相关论文
共 50 条
  • [31] PHASE III CLINICAL STUDY OF TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN COMBINATION TABLET IN PATIENTS WITH CHRONIC OSTEOARTHRITIS PAIN OR CHRONIC LOW BACK PAIN - A RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY
    Matsushita, Takashi
    Hasebe, Miki
    Nishimura, Akira
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S85 - S85
  • [32] A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee
    Kivitz, A
    Ma, C
    Ahdieh, H
    Galer, BS
    CLINICAL THERAPEUTICS, 2006, 28 (03) : 352 - 364
  • [33] The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
    Bolten, Wolfgang W.
    Glade, Michael J.
    Raum, Sonja
    Ritz, Barry W.
    ARTHRITIS, 2015,
  • [34] Efficacy and safety of a tramadol/acetaminophen combination (Ultracet™) in the management of fibromyalgia related pain.: A multicenter, outpatient, randomized, double-blind, placebo-controlled study.
    Bennett, R
    Kamin, M
    Rosenthal, N
    Karim, R
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S67 - S67
  • [35] A Randomized, Double-Blind, Double-Dummy Comparison of the Efficacy and Tolerability of Low-Dose Transdermal Buprenorphine (BuTrans® Seven-Day Patches) With Buprenorphine Sublingual Tablets (Temgesic®) in Patients With Osteoarthritis Pain
    James, Ian G. V.
    O'Brien, Catherine M.
    McDonald, Chris J.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2010, 40 (02) : 266 - 278
  • [36] Results of a multicenter, 8-week, parallel-group, randomized, double-blind, double-dummy, phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension
    Park, S
    Chung, N
    Kwon, J
    Yoon, JH
    Kim, YJ
    Han, DS
    Kim, HS
    CLINICAL THERAPEUTICS, 2005, 27 (04) : 441 - 450
  • [37] Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
    Jabbour, Serge A.
    Hardy, Elise
    Sugg, Jennifer
    Parikh, Shamik
    DIABETES CARE, 2014, 37 (03) : 740 - 750
  • [38] A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B First-stage results at week 48
    Liang, Rong-Yue
    Xu, Jing-Hang
    Si, Chong-Wen
    Wang, Sa
    Shang, Jia
    Yu, Zu-Jiang
    Mao, Qing
    Xie, Qing
    Zhao, Wei
    Li, Jun
    Gao, Zhi-Liang
    Wu, Shan-Ming
    Tang, Hong
    Cheng, Jun
    Chen, Xin-Yue
    Zhang, Wen-Hong
    Wang, Hao
    Xu, Zhong-Nan
    Wang, Ling
    Dai, Jun
    Yu, Yan-Yan
    MEDICINE, 2019, 98 (33)
  • [39] A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144
    Xu, Jinghang
    Yu, Yanyan
    Si, Chongwen
    Zeng, Zheng
    Li, Jun
    Mao, Qing
    Zhang, Dazhi
    Tang, Hong
    Sheng, Ji-Fang
    Chen, Xinyue
    Ning, Qin
    Shi, Guangfeng
    Xie, Qing
    Zhang, Xiquan
    Dai, Jun
    Xu, Zhongnan
    HEPATOLOGY, 2016, 64 : 925A - 925A
  • [40] A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240
    Xu, J. -H.
    Jing, C. -D.
    Chen, X. -F.
    Wang, S.
    Zeng, Z.
    Si, C. -W.
    Li, J.
    Mao, Q.
    Zhang, D. -Z.
    Tang, H.
    Sheng, J. -F.
    Chen, X. -Y.
    Ning, Q.
    Shi, G. -F.
    Xie, Q.
    Dai, J.
    Zhang, X. -Q.
    Xu, Z. -N.
    Yu, Y. -Y.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S517 - S518